---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-106362"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2024-09-13T23:59:59+00:00"
generated_at: "2026-05-31T04:56:54.659385+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Prelude reports Phase 1 interim data: PRT3789 shows 3 confirmed PRs in NSCLC/esophageal, well tolerated

## Summary
- 3 confirmed partial responses in 2 esophageal and 1 NSCLC patient out of 26 evaluable; 7 patients had tumor shrinkage.
- PRT3789 was well tolerated in 65 patients; no dose-limiting toxicities or drug-related serious adverse events.
- Dose escalation continues to cohort 9 (500 mg once weekly); MTD not yet reached.
- Company expects to confirm biologically active dose as monotherapy by year-end.
- Data presented at ESMO 2024; also selected for plenary session at EORTC-NCI-AACR Symposium in October 2024.

## SEC filing metadata
- accession: 0000950170-24-106362
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2024-09-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017024106362/0000950170-24-106362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017024106362/prld-20240913.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-106362
- JSON: https://secwatch.observer/filing/0000950170-24-106362.json
- Plain text: https://secwatch.observer/filing/0000950170-24-106362.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.